All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

Kymera Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Preclinical Protein Degrader Biotech Kymera Therapeutics Files for A $100 Million Ipo

Lead Product(s): KT-474

Therapeutic Area: Dermatology Product Name: KT-474

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Morgan Stanley

Deal Size: $100.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering July 31, 2020

Details:

Kymera expects to file an IND for KT-474, an orally bioavailable IRAK4 degrader, in the 1H 2021. If approved, the company will initiate a Phase 1 trial in adult healthy volunteers and hidradenitis suppurativa (HS) and atopic dermatitis (AD) patients.